Gibson, Dunn & Crutcher represented XOMA Corporation in the transaction, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Daré. XOMA Corporation (NASDAQ: XOMA) announced...
XOMA’s Acquisition of Economic Interest in Three Women’s Health Assets
ARCA Biopharma’s Merger with Oruka Therapeutics
Wilson Sonsini Goodrich & Rosati is advising ARCA biopharma, Inc. on the transaction, while Gibson, Dunn & Crutcher is advising Oruka Therapeutics and Cooley is advising...
Apogee Therapeutics’ $483 Million Common Stock Offering
Gibson, Dunn & Crutcher represented Apogee Therapeutics, Inc. in the offering, and Cooley represented the underwriters. Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company, announced the...
XOMA’s Acquisition of Kinnate Biopharma
XOMA was represented by Gibson, Dunn & Crutcher LLP. XOMA Corporation (NASDAQ: XOMA) announced it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for a...
Dianthus Therapeutics’ $230 Million Private Placement
Gibson, Dunn & Crutcher LLP represented Dianthus Therapeutics, Inc. on the placement. Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation...
XOMA’s $8 Million Acquisition of DSUVIA
Gibson, Dunn & Crutcher LLP advised XOMA Corporation on the expansion of its commercial royalty and milestone portfolio with the acquisition of an economic interest in...
Relay Therapeutics’ $30 Million Private Placement Financing
Gibson, Dunn & Crutcher LLP is advising Nextech on the matter. Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process...
Arrowhead Pharmaceuticals’ $450 Million Common Stock Offering
Gibson, Dunn & Crutcher LLP is advising Arrowhead Pharmaceuticals, Inc. on the offering. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced the pricing of an underwritten registered offering...
Pathos AI’s Acquisition of Rain Oncology
Leerink Partners is acting as exclusive financial advisor and Gibson, Dunn & Crutcher LLP is acting as legal counsel to Rain. Goodwin Procter LLP is acting...
89bio Inc.’s $172 Million Upsized Public Offering
Gibson, Dunn & Crutcher LLP advised 89bio, Inc. on its upsized public offering. 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
Royalty Pharma’s Partnership with Teva Pharmaceuticals International GmbH
Gibson, Dunn & Crutcher LLP advised Royalty Pharma in connection with its development funding. Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary...
Neurogene’s Merger with Neoleukin
Gibson Dunn & Crutcher LLP is serving as legal counsel to Neurogene Inc. and Fenwick & West LLP is serving as legal counsel to Neoleukin Therapeutics,...